Utility of an Immunohistochemical Panel Consisting of Glypican-3, Heat-shock Protein-70, and Glutamine Synthetase in the Distinction of Low-grade Hepatocellular Carcinoma From Hepatocellular Adenoma
- 1 March 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 21 (2) , 170-176
Abstract
Background: The pathologic distinction between hepatocellular carcinoma (HCC) and hepatocellular adenoma (HCA) is sometimes problematic due to histologic overlap between the 2 entities, a problem amplified on small biopsy specimens. Several recently characterized immunohistochemical markers such as glypican-3 (GPC-3), heat-shock protein-70 (HSP-70), and glutamine synthetase (GS) help distinguish dysplastic nodules from HCC. The utility of this panel in the distinction of low-grade hepatocellular carcinoma (LG-HCC) from HCA has not been fully described. Objective: To determine whether the above markers are useful in the distinction of HCCs from HCAs. Design: Tissue microarrays were constructed with 30 LG-HCCs and 18 HCAs. The arrays were stained with the above markers and analyzed with respect to amount and pattern of staining. GPC-3 and HSP-70 were considered positive when 10% of tumor cells showed immunoreactivity. GS was considered positive when 50% of tumor cells showed immunoreactivity. Results: GPC-3 was positive in 13 of 30 LG-HCCs and 0 of 18 adenomas. The sensitivity was 43% and the specificity was 100%. HSP-70 was positive in 14 of 30 LG-HCCs and 0 of 18 adenomas. The sensitivity was 46% and the specificity was 100%. GS was positive in 24 of 30 LG-HCCs and 9 of 18 adenomas. The sensitivity was 80% and the specificity was 50%. Conclusions: GPC-3 and HSP-70 are helpful in separating carcinomas from adenomas. GS is not useful in this clinical context.Keywords
This publication has 15 references indexed in Scilit:
- The Use of Immunohistochemistry in Liver TumorsClinics in Liver Disease, 2010
- The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional PerspectiveThe Oncologist, 2010
- Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer Science, 2009
- Hepatocellular carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinomaJournal of Hepatology, 2009
- Distinction of Hepatocellular Carcinoma From Benign Hepatic Mimickers Using Glypican-3 and CD34 ImmunohistochemistryAmerican Journal of Surgical Pathology, 2008
- Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistryHepatology, 2007
- Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosisHepatology, 2007
- Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like NodulesAmerican Journal of Surgical Pathology, 2006
- Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinomaHepatology, 2003